-->
In-house commercial-scale manufacturing facility with a 3D bioreactor technology for cell expansion
Placental cell therapies designed to treat patients by simulating the bodies' own regenerative mechanism
Certified GMP (good manufacturing practice) facility
One platform with multiple applications targeting significant unmet medical needs
CAROUSEL_DECEMBER_1200_5503

Landmark collaboration with Israel’s largest food producer, Tnuva Group, to establish cultured food platform

In-house commercial-scale manufacturing facility with a 3D bioreactor technology for cell expansion

In-house commercial-scale manufacturing facility with a 3D bioreactor technology for cell expansion

CAROUSEL_DECEMBER_1200_550

Placental cell therapies designed to treat patients by simulating the bodies' own regenerative mechanism

Placental cell therapies designed to treat patients by simulating the bodies' own regenerative mechanism

Placental cell therapies designed to treat patients by simulating the bodies' own regenerative mechanism

CAROUSEL_DECEMBER_1200_5504

In-house commercial-scale manufacturing facility with a 3D bioreactor technology for cell expansion and Certified GMP (good manufacturing practice) facility

Certified GMP (good manufacturing practice) facility

Certified GMP (good manufacturing practice) facility

CAROUSEL_DECEMBER_1200_5502

One platform with multiple applications targeting significant unmet medical needs

One platform with multiple applications targeting significant unmet medical needs

One platform with multiple applications targeting significant unmet medical needs

Shadow
  • Clinical Programs

  • Products

  • Science & Technology

  • Benefits
    BENEFITS
    Technology platform for cell products, targeting treatment for a range of indications
  • CELL PROFILING EXPERTISE
    CELL PROFILING EXPERTISE
    Deep understanding of the cell secretion profiles that generate therapeutic effects
  • MANUFACTURING FACILITY
    MANUFACTURING FACILITY
    Company owned and operated GMP-certified manufacturing and research facilities

News

13/07/2022

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
> Read More